Aldosterone and aldosterone synthase inhibitors in cardiorenal disease
Subodh Verma(St. Michael's Hospital), Deepak L. Bhatt(Mount Sinai Hospital), C. David Mazer(St. Michael's Hospital), Mikhail Kosiborod(AstraZeneca (Brazil)), Hwee Teoh(St. Michael's Hospital), Arjun Pandey(University of Ottawa), Kim A. Connelly(St. Michael's Hospital), Francesco Cosentino(Linköping University), John S. Lee(PhaseBio Pharmaceuticals (United States)), Stefan D. Anker(Bayer (Germany)), Avinash Pandey(University of Ottawa), Javed Butler(Jackson Memorial Hospital)
American Journal of Physiology-Heart and Circulatory Physiology
December 22, 2023
Cited by 53
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k